YOLFTbeta
InnoTherapy Inc

InnoTherapy Inc

246960 · KQ · Healthcare / Medical Devices

1,989.00KRW+40.00 (+2.05%)

Price History

Full chart

Market Stats

Previous Close1,949.00
Open1,999.00
Day Range1,859.00 – 2,000.00
52-Week Range1,389.00 – 3,250.00
Volume106.76K
Market Cap86.40B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.55
50-Day Avg2,122.92
200-Day Avg2,051.23

About

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK and InTro vascular interventional procedure items; and operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024. SCL Science Inc. was founded in 2010 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Moon Sue Lee
  • Employees61
  • Headquarters#1206~1210, Ace High Tech City 2-complex, Seoul, South Korea, 07282, Korea
  • Websitehttps://www.innotherapy.com

Leadership

  • Dr. Moon Sue LeeFounder & CEO
  • Mr. Hae-Shin LeeFounder & CTO · b. 1973
  • Mr. In Keun MoonCFO, COO & VP
  • Mr. Hong Kee Kim Ph.D.Head of Research & Development Center
  • Ms. Mi Young Koh Ph.D.Head of Product Development Center
  • Mr. Chang Yeon KimPresident of InnoTherapy America, Inc.

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue13.64M100.54M202.72M512.20M692.76M596.19M507.29M369.78M1.32B4.74B22.01B
Growth (%)-+637.30%+101.63%+152.67%+35.25%-13.94%-14.91%-27.11%+257.54%+258.30%+364.64%
Cost of Revenue3.35M126.21M190.17M293.83M328.25M256.86M323.79M301.37M1.11B2.93B17.81B
Gross Profit10.29M-25.67M12.55M218.38M364.51M339.33M183.49M68.41M208.41M1.81B4.20B
Gross Margin75.43%-25.53%6.19%42.64%52.62%56.92%36.17%18.50%15.76%38.18%19.09%
Operating Expense1.39B1.73B3.01B2.80B4.27B3.26B4.85B4.67B7.20B5.47B7.60B
Operating Income-1.38B-1.76B-2.99B-2.59B-3.90B-2.92B-4.67B-4.61B-6.99B-3.66B-3.40B
Operating Margin-10086.39%-1750.87%-1476.80%-504.93%-563.06%-490.45%-919.67%-1245.42%-528.55%-77.28%-15.44%
EBITDA--------4.35B-3.49B-2.34B393.27M
EBITDA Margin--------1177.44%-264.15%-49.32%1.79%
Net Income-4.82B-777.82M-3.01B-2.57B-3.99B-3.05B-5.03B-5.97B-5.03B-3.73B-3.93B
Net Income Margin-35369.61%-773.63%-1485.79%-502.60%-575.82%-511.16%-991.39%-1614.99%-380.17%-78.74%-17.87%
R&D264.01M333.84M652.19M816.41M-1.24B1.42B1.34B1.24B1.66B1.88B
R&D as % of Total Revenue1936.05%332.04%321.73%159.39%-207.77%280.56%361.83%93.43%35.11%8.55%
Interest Expense0000055.49M564.66M874.14M730.77M261.34M2.12B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%9.31%111.31%236.40%55.27%5.52%9.63%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.11B7.03B4.20B11.18B17.23B17.35B31.88B30.81B30.16B24.06B79.92B
Total Liabilities14.34B957.90M1.11B1.66B2.15B4.41B21.80B17.77B11.26B8.54B56.43B
Total Equity-6.99B6.07B3.10B9.52B15.08B12.94B10.08B13.05B18.90B15.52B24.45B
Cash2.38B1.07B222.05M341.59M5.85B575.63M1.03B927.12M5.05B937.09M4.17B
Total Debt--500.00M800.00M454.84M2.63B-----
Net Debt-----2.14B9.78B9.37B2.26B2.89B18.32B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.15B-1.12B-2.26B-2.18B-3.26B-2.87B-3.98B-4.10B-2.82B-5.96B-1.03B
Investing Cash Flow-3.41B55.74M812.16M-7.12B-867.50M-4.26B-14.51B5.04B1.53B5.65B-
Financing Cash Flow6.81B-10.80M500.00M9.30B9.63B1.86B18.94B-139.61M4.51B-3.81B-
Capital Expenditure2.40B1.08B62.53M27.83M285.38M1.82B6.34B890.29M2.90B2.55B3.61B
Free Cash Flow-----4.50B-4.69B-10.33B-4.99B-5.72B-8.51B-4.64B
FCF to OCF----137.85%163.38%259.23%121.69%202.81%142.82%450.82%

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------
EPS Actual-72.56-44.25-36.84-47.54-47.36-43.16-49.33-11.19-57.47-57.91-22.66-111.22-79.13-69.18-82.03-50.40-53.52-141.8318.82-24.37-21.35-33.91-28.23-44.81-55.526.12-3.58-70.64-25.00-0.28
Surprise------------------------------
Timing------------------------------

Key Statistics & Ratios

Market Cap86.40B
Enterprise Value117.28B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.83
Price / Book3.84
Revenue (TTM)30.50B
Gross Profit (TTM)7.00B
EBITDA2.99B
Profit Margin-11.10%
Operating Margin5.34%
Return on Equity-14.54%
Return on Assets-0.83%
Shares Outstanding34.01M
Shares Float15.61M
Beta0.55
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 30, 20254:1